Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026
The Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti CD19 Antibody Pipeline Insights - 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
ANTI-CD19 ANTIBODY
• CD19 is a 95-kDa transmembrane glycoprotein, which belongs to the immunoglobulin (Ig) superfamily and can act as a central positive response regulator in B cells. The CD19 has been expressed on the surface of leukemia cells in > 90% of cases with acute lymphoblastic leukemia (ALL).
• Moreover, it can be expressed on tumor cells of cases with both B-cell NHL and chronic lymphocytic leukemia (CLL).
• Thus, the CD19 antigen is an ideal target for immunotherapy of B-cell malignancies. CD19 can act as a B cell co-receptor in conjunction with both CD21 and CD81. Genetic studies show that CD19 has a role in keeping a balance between immunity and autoimmunity.
• Antibody-drug conjugates (ADCs) comprise an antibody, which is joined to a cytotoxic drug by a linker are promising new therapeutic anticancer drugs. Currently, over 30 ADCs are found that are being investigated in the early or late stage of clinical trials.
• The primary focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. However, efforts are also being made to use these therapies in the treatment of other indications including certain autoimmune diseases and solid tumors.
• Post initial researches in CAR-T therapies; many non-industry players have entered into collaborations with industry stakeholders to fund the clinical and commercial development of these products. Some late-stage products that have emerged out of such partnerships include KTE-C19, CTL019, JCAR015, and JCAR017.
• The recent approval of BLINCYTO®, a CD19 targeting bsAb, and the emergence of CAR-T therapies has provided a significant boost to this market that has actively evolved in the past few years.
• During our research, we identified over 50 products in various phases of development. Of these, 70% are in the clinical phase of development (with one molecule in phase II/III trial and six molecules in phase II stage).
• – CAR-T therapies (constituting 70% of the development pipeline) are the most common, followed by bsAbs (11%), ADC (7%) and engineered antibodies (7%).
• Many anti-CD19 IgG1 antibodies with cytotoxicity-improved Fc? part and three drug conjugated antibodies including coltuximabravta-nine (SAR3419) by ImmunoGen Inc., Sanofi-aventis, lintuzumab-mandolin (SGN-CD19A) by Seattle Genetics and taplitu -momabpaptox are now in phase 1/2 trials and the most advanced is the anti-CD19/CD3 BiTE antibody blinatumomab, by Amgen, Which is in phase 1 trial in patients with NHL and was approved by FDA for precursor B-cell ALL therapy on December 3, 2014. XmAb5871, which was generated by Amgen and Xencor Inc, MDX-1342 by Medarex (Bristol-Myers Squibb), AFM11 by Affimed Therapeutics AG are in phase 1 trials of drug development. MOR-208 (XmAb5574) is in stage 2 and was developed by Xencor and MorphoSys AG as a therapeutic drug for NHL and ALL. MEDI-551 can target CD19 on B cells and entered phase 2 trials in 2011 by MedImmune.
• The factors driving the global anti-CD 19 antibody therapeutics market are high incidence rates of non-Hodgkin’s lymphoma (NHL), the rise in investment in health care by the government and private organizations, increase in demand for minimally invasive surgeries, growing awareness about health, and early diagnosis of diseases.
• However, the rise in the cost of treatment, side effects associated with treatment, and lack of reimbursement policies in developing countries such as India, Singapore, and Brazil are likely to restrain the market.
• CD19 is a 95-kDa transmembrane glycoprotein, which belongs to the immunoglobulin (Ig) superfamily and can act as a central positive response regulator in B cells. The CD19 has been expressed on the surface of leukemia cells in > 90% of cases with acute lymphoblastic leukemia (ALL).
• Moreover, it can be expressed on tumor cells of cases with both B-cell NHL and chronic lymphocytic leukemia (CLL).
• Thus, the CD19 antigen is an ideal target for immunotherapy of B-cell malignancies. CD19 can act as a B cell co-receptor in conjunction with both CD21 and CD81. Genetic studies show that CD19 has a role in keeping a balance between immunity and autoimmunity.
• Antibody-drug conjugates (ADCs) comprise an antibody, which is joined to a cytotoxic drug by a linker are promising new therapeutic anticancer drugs. Currently, over 30 ADCs are found that are being investigated in the early or late stage of clinical trials.
• The primary focus of these novel molecules is hematological cancers, specifically B cell malignancies, with CAR-T therapies leading the table. However, efforts are also being made to use these therapies in the treatment of other indications including certain autoimmune diseases and solid tumors.
• Post initial researches in CAR-T therapies; many non-industry players have entered into collaborations with industry stakeholders to fund the clinical and commercial development of these products. Some late-stage products that have emerged out of such partnerships include KTE-C19, CTL019, JCAR015, and JCAR017.
• The recent approval of BLINCYTO®, a CD19 targeting bsAb, and the emergence of CAR-T therapies has provided a significant boost to this market that has actively evolved in the past few years.
• During our research, we identified over 50 products in various phases of development. Of these, 70% are in the clinical phase of development (with one molecule in phase II/III trial and six molecules in phase II stage).
• – CAR-T therapies (constituting 70% of the development pipeline) are the most common, followed by bsAbs (11%), ADC (7%) and engineered antibodies (7%).
• Many anti-CD19 IgG1 antibodies with cytotoxicity-improved Fc? part and three drug conjugated antibodies including coltuximabravta-nine (SAR3419) by ImmunoGen Inc., Sanofi-aventis, lintuzumab-mandolin (SGN-CD19A) by Seattle Genetics and taplitu -momabpaptox are now in phase 1/2 trials and the most advanced is the anti-CD19/CD3 BiTE antibody blinatumomab, by Amgen, Which is in phase 1 trial in patients with NHL and was approved by FDA for precursor B-cell ALL therapy on December 3, 2014. XmAb5871, which was generated by Amgen and Xencor Inc, MDX-1342 by Medarex (Bristol-Myers Squibb), AFM11 by Affimed Therapeutics AG are in phase 1 trials of drug development. MOR-208 (XmAb5574) is in stage 2 and was developed by Xencor and MorphoSys AG as a therapeutic drug for NHL and ALL. MEDI-551 can target CD19 on B cells and entered phase 2 trials in 2011 by MedImmune.
• The factors driving the global anti-CD 19 antibody therapeutics market are high incidence rates of non-Hodgkin’s lymphoma (NHL), the rise in investment in health care by the government and private organizations, increase in demand for minimally invasive surgeries, growing awareness about health, and early diagnosis of diseases.
• However, the rise in the cost of treatment, side effects associated with treatment, and lack of reimbursement policies in developing countries such as India, Singapore, and Brazil are likely to restrain the market.
